SeekingAlpha · Jan 11, 2026
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow
2026-01-11. The following slide deck was published by Jasper Therapeutics, Inc.
NASDAQ · JSPRW
Healthcare · Biotechnology
$0.01
Up+$0.00 (+0.00%)
Updated Sep 19, 2026, 10:26 PM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 17 trading sessions · Daily adjusted prices
JSPRW closed at $0.01 after 17 trading sessions, down 58.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $0.0031 | $0.005 | $0.0031 | $0.005 | 26.76K |
| Sep 17, 2026 | $0.0031 | $0.005 | $0.0031 | $0.005 | 13.54K |
| Sep 16, 2026 | $0.0075 | $0.0075 | $0.003 | $0.0049 | 184.04K |
| Sep 15, 2026 | $0.0074 | $0.0074 | $0.0056 | $0.0073 | 44K |
| Sep 14, 2026 | $0.0079 | $0.008 | $0.0067 | $0.008 | 12.44K |
| Sep 11, 2026 | $0.0057 | $0.008 | $0.0057 | $0.008 | 22.69K |
| Sep 9, 2026 | $0.0092 | $0.0092 | $0.0057 | $0.0085 | 62.59K |
| Sep 8, 2026 | $0.0057 | $0.0074 | $0.0057 | $0.0074 | 1.15K |
| Sep 2, 2026 | $0.0057 | $0.0092 | $0.0057 | $0.0092 | 3.35K |
| Sep 1, 2026 | $0.0072 | $0.0092 | $0.0065 | $0.0092 | 7.24K |
| Aug 31, 2026 | $0.0046 | $0.009 | $0.0046 | $0.009 | 10.44K |
| Aug 28, 2026 | $0.0053 | $0.0093 | $0.0053 | $0.0089 | 13.41K |
| Aug 27, 2026 | $0.0079 | $0.009 | $0.0077 | $0.009 | 15.94K |
| Aug 26, 2026 | $0.012 | $0.012 | $0.0025 | $0.0099 | 124.25K |
| Aug 25, 2026 | $0.0092 | $0.012 | $0.0074 | $0.0099 | 62.28K |
| Aug 24, 2026 | $0.0073 | $0.0119 | $0.0073 | $0.0109 | 10.12K |
| Aug 21, 2026 | $0.0074 | $0.012 | $0.0074 | $0.012 | 16.37K |
The latest Smart Investors Daily articles mentioning JSPRW.
JSPRW research
Company profile and research snapshot.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Jan 11, 2026
2026-01-11. The following slide deck was published by Jasper Therapeutics, Inc.
SeekingAlpha · Jan 8, 2026
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria January 8, 2026 8:00 AM ESTCompany...
GlobeNewswire Inc. · Nov 10, 2025
A class action lawsuit has been filed against Jasper Therapeutics alleging false and misleading statements about manufacturing controls, product prospects, and potential regulatory issues during the period of November 30, 2023 to July 3, 2025.
GlobeNewswire Inc. · Nov 3, 2025
Jasper Therapeutics faces a class action lawsuit alleging securities fraud after revealing issues with a drug product lot that impacted clinical trial results, leading to study halts and significant stock price decline.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning JSPRW.
No results
No recent SID articles mention JSPRW.